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Abstract
Colorectal cancer is known to be one of the most commonly diagnosed cancers world-
wide. It maintains a high mortality rate despite the newest methodological therapeutic 
approaches adopted in various academic establishments. The treatment modalities in 
colorectal cancer follow the degree of disease progression based on staging information. 
Earliest the cancer is diagnosed, the highest the possibility to be cured. Different strate-
gies are being involved in treating colorectal cancer, starting from simple endoscopic 
polypectomy to remove a potential malignant polyp, to wider surgical intervention to get 
rid of a primary unmetastasized tumor, to other concomitant radio-chemotherapy com-
binations to reduce a bulky tumor rendering it operable, ending in more sophisticated 
chemotherapeutical regimens combined with targeted drugs to shrink the metastatic 
lesions and prolong survival rate. Different new treatments are being investigated with a 
sole aim to preserve the patient’s quality of life and extend life span.
Keywords: colorectal cancer, colorectal polyps, chemotherapy, targeted therapy, 
immunotherapy, Lynch syndrome, familial adenomatous polyposis syndrome
1. Introduction
Colorectal cancers (CRC) are considered the third most commonly diagnosed cancers in the 
world. The incidence and mortality rates vary worldwide from lowest in Africa and Asia to 
highest in Australia, North America, and Europe. The etiology is mainly due to changes in 
dietary habits, from low-fiber ingestion to high-fat diet, increased body mass index (BMI), 
low physical activity, cigarette smoking, alcohol consumption, diabetes mellitus, ulcerative 
colitis, Crohn’s disease, some inherited syndromes (familial adenomatous polyposis syn-
drome and nonpolyposis colorectal cancer or Lynch syndrome (LS), MUTYH-associated 
and Turcot-associated polyposis syndromes, Peutz-Jeghers syndrome, Juvenile polyposis 
syndrome, and Cowden syndrome), in addition to radiation therapy for another abdominal 
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cancer [1–3]. Early diagnosis is necessary to get full remission, and screening has proved to 
be fundamental in decreasing the mortality rate. The treatment of CRC is multidisciplinary 
and implies a collaboration of many therapeutic teams including surgical, chemotherapy, 
as well as radiotherapy experts. In the following chapter, we will be studying the different 
treatment modalities and strategies approved and administered worldwide, according to 
CRC stages.
The staging classification of CRC has been conceived according to collaboration between the 
Union for International Cancer Control (UICC) and the seventh edition of the American Joint 
Committee on Cancer (AJCC-7), taking into consideration the Dukes’ staging with its modifi-
cations by Astler-Coller (MAC) and Kirklin system (Table 1).
Stage UICC/AJCC Dukes MAC
0 Tis N0 M0 — —
I T1 N0 M0 A A
T2 N0 M0 A B1
II A T3 N0 M0 B B2
B T4a N0 M0 B B2
C T4b N0 M0 B B3
III A T1–T2 N1–N1c M0 C C1
T1 N2a M0 C C1
B T3–T4a N1–N1c M0 C C2
T2–T3 N2a M0 C C1–C2
T1–T2 N2b M0 C C1
C T4a N2a M0 C C2
T3–T4a N2b M0 C C2
T4b N1–N2 M0 C C3
IV A Any T Any N M1a D D
B Any T Any N M1b D D
Tis, Tumor confined to the mucosa; T1, tumor invades the submucosa; T2, tumor invades the muscularis propria; T3, 
tumor invades subserosa or beyond, without invading other organs; T4, tumor invades nearby organs (T4a, without 
perforation of visceral peritoneum; T4b, with perforation of visceral peritoneum); N1, metastasis to one to three regional 
lymph nodes (RLNs) (N1a, metastasis to one RLN; N1b, metastasis to two to three RLNs; N1c, metastasis into areas of 
fat near lymph nodes but not the nodes themselves); N2, metastasis to four or more RLNs (N2a, metastasis to four to six 
RLNs; N2b, metastasis to seven or more RLNs); M1, distant metastases present (M1a, metastasis to distant organ, as the 
liver or lung, or distant set of lymph nodes; M1b, metastasis to distant organs, to distant set of lymph nodes, or to distant 
parts of the peritoneum as the lining of the abdominal cavity).
Table 1. Anatomic AJCC-7 staging for CRC.
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2. Treatment of CRC by stage
2.1. Treatment of stage 0 CRC
In stage 0 colorectal cancer, the tumor is still confined to the inner lining of the colon (T in situ). 
A surgical removal of the cancer is all that is needed. A polypectomy or a colonoscopic local 
excision is usually sufficient. Partial colectomy is required in case of bigger tumors.
2.2. Treatment of malignant polyps
2.2.1. Definition, classification, and staging
Malignant polyps are adenomas that have been identified histologically, after endoscopic 
excision, to be adenocarcinomas which have invaded through the muscularis mucosa into 
the basic submucosa (pT1) [4]. They can occur sporadically or as part of a polyposis syn-
drome. They can be classified endoscopically by their size and morphology and histologically 
as favorable (low risk) and unfavorable (high risk). In 1985, Haggitt reconceived the Japanese 
society classification and the Paris endoscopic classification into a new one taking into consid-
eration the level of invasion depth (Table 2).
Despite the big advantage and wide use of Haggitt’s classification in assessing the quality 
of resection of endoscopic polypectomies, the sessile, flat, or depressed lesions yet were not 
successfully evaluated using this classification. In the early 1990s, Kikuchi succeeded in quan-
tifying the grade of vertical and horizontal submucosal invasion, dividing the invasion into 
three levels (Table 3).
Morphologically, polyps are known to be either pedunculated or sessile. Pedunculated pol-
yps are usually attached to the colonic mucosa via a stalk of variable length, while sessile 
polyps are devoid of stalk, are flattened in shape, and overlay the mucosa with less separation 
of the adenomatous epithelium part from the underlying layers of the colon [5].
Histologically, polyps can be divided into low-risk versus high-risk features (Table 4) [4].
Level Location of carcinoma
0 Carcinoma in situ or confined to the mucosa. Not invasive
I Carcinoma invading through the muscularis mucosa into the submucosa but limited 
to the head of the polyp
II Carcinoma invading the level of the neck of the polyp
III Carcinoma invading in any part of the stalk of the polyp
IV Carcinoma invading into the submucosa of the bowel wall below the stalk of the 
polyp but above the muscularis propria
Table 2. Haggitt’s classification according to the level of invasion.
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2.2.2. Treatment
All of the aforementioned classifications are mandatory for accurate assessment of the degree 
of malignancy and aggressiveness of the resected polyp for rational clinical decision. Studies 
have shown polyps smaller than 5 mm in diameter, have negligible risk of malignancy, and 
are easily managed by standard techniques of endoscopic snare removal. Protruding polyps 
(Haggitt levels I, II, or III) with favorable histological features should be subjected to local exci-
sion or endoscopic polypectomy. Haggitt level IV lesions with favorable histology are consid-
ered low risk and can be favorably managed with endoscopic polypectomy provided margins 
are safe (>2 mm). Haggitt level IV protruding polyps and/or polyps exhibiting unfavorable fea-
tures should be surgically excised due to the high incidence of lymph node metastasis. Excision 
can be performed either through traditional open approach or via more conservative laparo-
scopic techniques [7]. For sessile non-protruding polyps, a wider excision should be recon-
sidered requiring endoscopic mucosal resection (EMR) or endoscopic submucosal dissection 
Low-risk features (favorable) High-risk features (unfavorable)
• Pedunculated (levels 1–3 according to Haggitt 
classification)
• Tumor budding
• Well-differentiated adenocarcinoma • Poorly differentiated adenocarcinoma (grade 3)
• Free resection margin (2 mm) • Positive, indeterminate, or <1 mm resection 
margin
• En bloc resection • Piecemeal removal
• Neither lymphatic nor vascular invasion • Presence of either lymphatic or vascular invasion
• Submucosal invasion Sm < 1 mm • Submucosal invasion Sm* >1 mm
*While Sm1a + b lesions have a very low risk for metastasis, the malignant potential increases with depth of submucosal 
invasion [6].
Table 4. Polyp classification according to histological criteria.
Submucosal level Submucosal invasion
Sm1* Characterizes lesions that are limited to the upper third of the submucosal layer
Sm1a Submucosal invasion under one fourth of tumoral width
Sm1b Submucosal invasion between one fourth and a half of the tumoral width
Sm1c Horizontal affection of the superior third of the submucosa over half of the 
tumoral width
Sm2 Characterizes lesions that are limited to the middle third of the submucosal layer
Sm3 Characterizes lesions that are limited to the lower third of the submucosal layer
*Sm1 lesions are further subdivided into three categories (a, b, and c) with regard to the degree of horizontal involvement 
of the upper submucosal layer (B), to the horizontal involvement of the total lesion (A). B/A ratios of 0.25, 0.25–0.5, and 
>0.5 correspond to a, b, and c, respectively.
Table 3. Kikuchi’s classification according to submucosal invasion level.
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(ESD) [4]. Endoscopic mucosal resection is more specific for removal of sessile polyps limited 
to the mucosa and submucosa (Sm1a + b) and is typically used for complete excision of lesions 
up to 2 cm [8]. Endoscopic submucosal dissection is usually adopted for larger gastrointestinal 
lesions, where it more easily promotes the en bloc resection, yet it carries greater risk of perfo-
ration (31%) and late bleeding (15%) [9]. Lesions with a deep level of invasion (Sm1c, Sm2, or 
Sm3) or rectal lesions (specifically those of the distal third) showed higher incidence of lymph 
node metastasis 12–25% and should be treated by a definitive oncologic segmental resection 
due to the high risk of regional lymph node involvement.
2.2.3. Surveillance
Local recurrence is basically common in managed malignant polyps. Regular endoscopic fol-
low-up is recommended to detect any disease recurrence; however, the duration of subsequent 
surveillance varies [10, 11]. In favorable histological criteria, protruding (levels I, II, or III), and 
noninvasive Sm1a + b polyps, it is recommended that a colonoscopy be carried out 3 months 
after the polypectomy [12, 13]. Further regular checkup is advised within 1, 3, and 5 years [14]. 
In malignant pedunculated polyps with unfavorable histological criteria, the risk of relapse or 
residual lesions reached 39% in treated patients. These patients are also found to have distant 
metastasis on follow-up, even 5 years after surgery [15]. Accordingly, in addition to the regu-
lar endoscopic surveillance, monitoring the serum level of carcinoembryonic antigen (CEA) 
and imaging techniques as computerized tomography or magnetic resonance imaging would 
enable early detection of disease recurrence. According to the American Cancer Society and the 
US Multi-Society Task Force on Colorectal Cancer’s guidelines, shorter follow-up intervals are 
recommended in case of senility, positive family history, or hereditary nonpolyposis colorec-
tal cancer (HNPCC). Furthermore, endoscopic ultrasound or flexible sigmoidoscopy at 3- to 
6-month intervals for the first 2 years after polypectomy can be considered for detecting early 
curable recurrences.
2.3. Treatment of stage I CRC
Stage I CRC includes T1 and T2, where cancer is still limited to and has not yet invaded 
the layers of the colon into other nearby organs. T1 cancers are usually parts of polyps that 
were discussed hereinabove. For T2 cancers, the standard of care consists of partial colectomy 
with regional lymph node dissection. A laparoscopic-assisted colectomy can be an acceptable 
choice for patients who are not candidates for open colectomy.
Stage I adenocarcinoma of the rectum is relatively rare, and a surgical removal of the cancer is 
usually curable. For the low-risk stage I rectal cancer, both endoscopic resection and transanal 
excision can be used. Transanal endoscopic microsurgery (TEM) is a transanal operation suit-
able for small tumors and not too far from the anus. It involves wide excision of all layers of 
the invaded rectum with the surrounding tissue to secure negative margins. If the cancer is 
located in the upper part of the rectum, a low anterior resection (LAR) is recommended, where 
the incision takes part across the abdomen to remove the affected rectum along with some 
surrounding tissue and lymph nodes, and followed by anorectal anastomosis. If the cancer 
occupies the lower part of the rectum (alongside the anus), an abdominoperineal resection 
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(APR) with permanent colostomy is advised, when the distance between tumor and anus is 
too short to allow safe anastomosis. No additional therapy is needed after these operations, 
unless the surgeon finds the cancer with high-risk features. Then, an adjuvant concomitant 
chemoradiotherapy is appropriate with 5-fluorouracil (5-FU) or capecitabine [16].
2.3.1. Surveillance
Regular follow-up testing after the end of treatment aims at seizing any early disease recur-
rence. Colonoscopy should be repeated 1 year after therapy completion. In case of normal 
results, the next checkup should be after 3 years and then after 5 years. In case of finding any 
advanced adenoma (polyps with ruffled structure, larger than 1 cm, or with high-grade dys-
plasia), colonoscopy should be repeated within 1 year [17].
2.4. Treatment of stage II CRC
2.4.1. Assessing risk factors
The role of adjuvant chemotherapy remains undetermined in stage II CRC. Surgical interven-
tion should aim at a wide resection of the tumor with the involved bowel segment, all together 
with cutting out of the lymphatic system draining that part. The resection should include at 
least 5 cm colon segment of either side of the resected tumor. For adequate tumor staging (II 
or III), and to determine and eliminate any possible lymph node metastases (pN), at least 12 
lymph nodes should be excised and subjected to histological analysis. Partial colectomy may be 
the only needed treatment for low- and medium-risk stage II CRC patients. High-risk patients 
should be subjected to chemotherapy if one of the following risk factors was identified:
• High pT4 stage (T4 or tumor invading into adherent organs)
• Suboptimal lymph node resection (less than 12)
• Presence of lymphovascular or perineural invasion
• Bowel obstruction or perforation
• Poorly differentiated histology
• High carcinoembryonic antigen (CEA) marker level
• Positive margins
Various additional risk factors are being implied in assessing the additive benefit to the high-risk 
factors in stage II colorectal cancer using adjuvant chemotherapy.
One of the most promising risk factors is the microsatellite instability (MSI)/mismatch repair 
(MMR), which is regarded as a good prognostic factor. Microsatellites are short, tandemly 
repeated DNA sequences in the genome that are susceptible to errors of DNA replication in 
the presence of a defective mismatch repair (MMR) system. They are detected in about 15% of 
all colorectal cancers and can be used to determine stage II patients who are at very low risk 
of recurrence and with low benefit of adjuvant chemotherapy [18, 19]. Moreover, it has been 
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established in a multivariate analysis that microsatellite instability was significantly associ-
ated with survival advantage independently of any other prognostic factors (hazard ratio 
(HR) 0.42; 95% confidence interval 0.27–0.67; p < 0.001) [20].
Another potential predictive colorectal marker is the allelic deletion of chromosome 18q, or 
the loss of heterozygosity (LOH) of chromosome 18, which is considered as a bad prognostic 
factor. The 18q loci hold several genes that are highly related to apoptosis and carcinogenesis. 
Patients (stage II or III) presenting 18qLOH were found to have less disease-free survival and 
overall survival than those with retained chromosome 18 (DFS 44% versus 64%, p = 0.002; OS 
50% versus 69%, p = 0.005) [21].
Another prognostic marker in CRC is the expression of guanylyl cyclase C (GCC) in resected 
lymph nodes. GCC is a protein that is usually expressed by intestinal cells but universally 
overexpressed in colorectal cancer. GCC is an intestinal tumor-suppressing receptor which 
regulates epithelial homeostasis. Silencing of GCC contributes to tumorigenesis by reflecting 
dysregulation of the cell cycle and DNA repair [22]. The presence of GCC in resected lymph 
nodes reflects the detection of prognostically important occult metastases [23].
The Kirsten rat sarcoma (KRAS) oncogene is a proto-oncogene involved in the normal tissue 
signaling pathways. KRAS mutation can occur via a single amino acid substitution or a single 
nucleotide substitution. The resulting protein is implicated in various malignancies, includ-
ing colorectal cancer [24]. Even though the British QUASAR trial in 2007 did not succeed to 
show any significant difference in overall survival between fluorouracil-treated and folinic 
acid–treated observation groups in stage II CRC [25], the risk of disease recurrence was found 
significantly higher for KRAS-mutant than KRAS wild-type tumors (28% versus 21%), and the 
risk of recurrence appeared larger in KRAS-mutant rectal than colon tumors [26].
The tumor suppressor TP53, or genome guardian, is another important predictive prognostic 
factor in CRC. TP53 is the most commonly mutated gene in human cancers, and its prevalence 
in CRC comprises 34% of the proximal colon tumors where it is mostly related to lymphatic 
invasion and 45% of the distal colorectal tumors where it is majorly correlated with lympho-
vascular invasion [27]. Clinical studies have shown that CRC patients with mutant p53 are 
more 5-fluorouracil-based chemotherapy resistant and have poorer prognosis than those with 
wild-type p53 [28].
The transforming growth factor beta (TGF-β) signaling pathway plays a central but paradoxi-
cal role in the predisposition and progression of colorectal cancer. TGF-β acts as a potent tumor 
suppressor in normal intestinal epithelial cells by inhibiting cell proliferation and inducing 
apoptosis. However, mutations in the genes encoding for TGFB receptor 2 (TGFBR2), with 
high levels of microsatellite instability, promote colon tumorigenesis by perturbing the func-
tion of TGF-β signaling pathways and stimulating the proliferation and invasion of poorly 
differentiated and metastatic colon cancer cells [29, 30].
Thymidylate synthase (TS) is an enzyme implicated in the formation of thymidine, one of DNA 
nucleotides. It catalyzes the methylation of deoxyuridine monophosphate (dUMP) to deoxythy-
midine monophosphate (dTMP). This role in nucleotide metabolism has made TS an important 
target of many chemotherapeutic agents such as 5-FU and the new folate-based TS inhibitors 
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(raltitrexed and pemetrexed). Elevated intracellular TS levels have been implicated in emerging 
resistance to fluoropyrimidines and other TS inhibitors due to the increase in transcription and 
translation roles of TS. Therefore, high TS expression in early-stage CRC patients is correlated to 
a poorer overall survival in both chemotherapy-treated and chemotherapy-untreated patients 
following surgery [31].
2.4.2. Choice of chemotherapy
5-Fluorouracil remains the backbone chemotherapy in treating CRC. In MOSAIC study, 
patients with stage II or III disease were randomly assigned to receive adjuvant FOLFOX4 
or 5-FU/leucovorin (LV). In stage II disease, no improvement in DFS or OS was noted in 899 
patients upon adding oxaliplatin to 5-FU (DFS HR = 0.84, p = 0.258; OS HR = 1.00, p = 0.986). 
Moreover, in patients with high-risk stage II disease, the estimated 10-year overall survival 
was 75.4% in FOLFOX arm versus 71.7% in 5-FU/leucovorin arm (p = .058) [19]. Similar 
results were obtained with the NSABP C-07 trial, where patients were randomized to receive 
either bolus 5-FU/LV alone or with oxaliplatin. While the addition of oxaliplatin to 5-FU/
LV improved DFS, no benefit in OS was observed at all [32]. Furthermore, the QUASAR 
study investigated the role of adjuvant 5-FU in disease recurrence in “average-risk” patients 
(patients without any high-risk feature). As a result, 5-FU decreased the risk of recurrence 
compared to observation alone (relative risk (RR) for colon cancer = 0.78, p = 0.004; RR for rec-
tal cancer =0.68, p = 0.004). And, the risk of death was improved in treated patients (RR = 0.84; 
p = 0.046), with an absolute survival benefit of 3.6% [25]. A major predictive prognostic fac-
tor in stage II CRC is microsatellite instability. As known, microsatellites are repeated DNA 
sequences in the genome. They are very susceptible to errors in DNA replication and espe-
cially in case of a defective mismatch repair (MMR) system, where they really can substi-
tute it [19]. In colon cancer, the high level of MSI is associated with mutations in the MMR 
system. Based on findings from over 7000 patients classified as MSI-high (MSI-H), MSI-low 
(MSI-L), or MSI-stable (MSS) colon cancers, those with MSI-H had a better prognosis com-
pared to those with MSI-L or MSS tumors by 15% [33]. Another important predictive factor 
in stage II CRC is 18qLOH. Loss of heterozygosity of chromosome 18 is highly associated 
with decreased overall survival [21, 34, 35]. The ECOG 5202 trial aimed at stratifying patients 
according to the molecular prognostic factors, MSI and 18qLOH. The recommendations were 
for stage II patients with low-risk (MSI-H or with either MSS or MSI-L together with 18qLOH 
retention) observation without any treatment. However, for those with high-risk observation 
(either MSS or MSI-L with 18qLOH), chemotherapy with FOLFOX is suggested [19].
As a conclusion for stage II CRC adjuvant treatment, the following algorithm is reasonable 
(Table 5).
2.4.3. Access to radiotherapy
According to Johns Hopkins colorectal health team, radiotherapy can be used adjuvantly in 
case of pT4, where the lesion is fixed and adherent to the abdominal wall or bladder, as it pro-
vides a lower chance of recurrence. Similarly, in case of rectal cancer, neoadjuvant chemoradio-
therapy is indicated in order to shrink the tumor size prior to surgery and to avoid colostomy if 
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possible. Radiotherapy is indicated when the rectal tumor has invaded the wall of the bowel or 
has spread into adjacent lymph nodes. 5-Fluorouracil or capecitabine are being used concomi-
tantly with radiotherapy to sensitize tumor cells to radiation. In addition, concomitant chemo-
radiotherapy is indicated when the margins of resection are positive. However, no significant 
differences in overall survival were reported till now. EORTC 22921 was one randomized trial 
of 1011 patients that assessed the role of adjuvant 5-FU after preoperative chemoradiation for 
patients with T3 or T4 resectable tumor. Patients were divided in four arms including preop-
erative radiotherapy with or without chemotherapy and preoperative radiotherapy with or 
without chemotherapy followed by adjuvant chemotherapy. The OS for a median follow-up of 
10.4 years was similar in the four groups (48.4–52.9%). There were no differences either in DFS 
rates or in the cumulative incidence of distant metastases [36]. A number of treatment strategies 
have been recently studied by various clinical trials, yet still no conclusive decisions have been 
taken. The major aim remains the patient’s benefit from a better tumor resection with less side 
effects, longer survival, and minor recurrence rates.
2.4.4. Surveillance
Survivorship care is a follow-up that takes place after the end of treatment to provide a better 
disease control and a less recurrence morbidity. A thorough physical examination with a tumor 
marker CEA should be performed systematically every 3–6 months for 2 years. In case of nor-
mal results, the frequency can be reduced to 6 months for an additional 3 years. Radiological 
imaging including CT scans or MRIs is indicated once a year for a total of 5 years. Colonoscopy 
is also suggested at an interval of 1 year after treatment and then after 3 and 5 years if results 
are normal.
2.5. Treatment of stage III CRC
Stage III colon cancer is characterized by tumor of any size (T1–T4) with metastasis to regional 
lymph nodes. A partial colectomy to remove the involved part of the colon along with adjacent 
lymph nodes, followed by adjuvant chemotherapy (not beyond 8 weeks of surgery), is considered 
Low risk (with MSI-H or with either MSS or MSI-L and 
retention of 18qLOH)
Observation
Average risk (with MSS) Observation or fluoropyrimidine* as single agent 
(optional)
High risk**:
• (with MSI-H and 18qLOH retention)
• (with MSS or MSS-L and 18qLOH)
• Fluoropyrimidine as single agent
• FOLFOX or CAPOX***
*Fluoropyrimidines are a class of antimetabolites that are converted in the body to 5-fluorouracil. These include 
5-fluorouracil, capecitabine, doxifluridine, tegafur, and carmofur.
**The high-risk factors are mentioned hereinabove in the text.
***FOLFOX denotes folinic acid/5-FU/oxaliplatin; CAPOX denotes capecitabine/oxaliplatin.
Table 5. Stage II CRC adjuvant treatment algorithm.
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the standard of care for this stage. However, in rectal cancer, tumor size (T3–T4, with invasion 
through intestinal muscular layer) with clinical positive lymph nodes is suggestive for neoadju-
vant chemoradiotherapy and followed by adjuvant chemotherapy for a lower risk of recurrence 
rate. The European Society for Medical Oncology (ESMO) guidelines recommended in 2013 a 
stratification of the risk factors for disease recurrence of rectal cancer according to the following 
items identified by pretreatment MRI. These included the tumor invasion depth (T staging), the 
number of metastatic lymph nodes (N staging), the distance to anus, invasion of mesorectal fascia 
(MRF), and extramural vascular invasion (EMVI). Four risk groups were stratified (ultralow-, 
low-, medium-, and high-risk groups). Surgery alone was the choice for the ultralow-risk group, 
while neoadjuvant chemoradiotherapy with adjuvant chemotherapy was the best choice for the 
medium- and high-risk groups; the low-risk group showed a beneficial effect of adding chemo-
radiotherapy or chemotherapy [37]. These findings are compatible with the NCCN guidelines 
which recommended neoadjuvant chemoradiotherapy and adjuvant chemotherapy for those 
patients with high risk of local recurrence, including stage II (T3–T4, with tumor invading through 
the intestinal muscle layer) and stage III (positive lymph nodes) [17].
2.5.1. Choice of chemotherapy
After a wide surgical resection with anastomosis, the standard chemotherapy protocol is 
approved to be oxaliplatin and 5-FU/folinic acid (FOLFOX4 or FLOX). In the MOSAIC study, the 
addition of oxaliplatin to 5-FU/LV (FOLFOX) showed a significantly increased DFS at 6 years, 
with a reduction in the risk of recurrence of 23% compared with the control arm (5-FU/LV), with 
an OS absolute gain of 4.2%. Similar results were obtained in the NSABP C-07 study, either in 
DFS at 3 years or in terms of reduction in the risk of recurrence. As a result of these studies, 
FOLFOX has been adopted adjuvantly on a biweekly basis, for a period of 12 cycles. In case 
of contradiction to oxaliplatin, 5-FU/LV administered intravenously according to de Gramont, 
AIO, or Mayo Clinic regimen, or oral fluoropyrimidines (capecitabine) are comparable in ben-
efit. Other drugs such as topoisomerase I inhibitor (irinotecan) or anti-VEGFR agent (bevaci-
zumab) or KRAS wild-type drug (cetuximab) did not succeed in adding any advantage either in 
DFS or in OS in stage III colon cancer [38].
In neoadjuvant rectal treatment, 5-fluorouracil remains the standard chemotherapeutic agent 
to be administered concomitantly with radiation. In ASCO 2011, NASBP R-04 firstly randomly 
compared the effect of capecitabine (an oral fluoropyrimidine) and 5-FU in preoperative con-
current chemoradiotherapy of rectal cancer. The results showed neither significant difference 
in pathological complete response (pCR) rate nor in third and fourth degree of adverse reac-
tion rate [39]. Recently, in Germany, a randomized clinical phase III multicenter non-inferior-
ity study showed no statistical difference of 3 years of DFS and local recurrence rate between 
capecitabine and 5-FU, concluding that capecitabine can substitute 5-FU as adjuvant or neoad-
juvant chemotherapy for locally advanced rectal cancer [40]. The role of oxaliplatin in radio-
therapy has been thoroughly examined as in many randomized studies as STAR-01, ACCORD 
12/0405, NSABP R-04, and PETACC 6. Unfortunately, neither study succeeded in showing 
any significant increase of the pCR rate or downstage rate comparing to single drug (5-FU or 
Colorectal Cancer - Diagnosis, Screening and Management42
capecitabine). In addition, ACCORD 12/0405 reported same OS (88%) in both combined two 
drugs (capecitabine with oxaliplatin) and single drug (capecitabine) [39, 41]. As a conclusion, 
single-agent fluoropyrimidine (5-FU or capecitabine) used concomitantly with pelvic radio-
therapy remains the standard of care in stage III CRC.
2.5.2. Surveillance
Regular follow-up is highly advised in stage III CRC due to the high rate of recurrence. Detecting 
early relapse can be performed through a meticulous regular physical checkup with tumor 
marker CEA every 3 months for the first 2 years. A thoraco-abdomino-pelvic CT scan is required 
every 6 months for the first 2 years. A colonoscopy is advised in a 6-month period for the first year 
after treatment. The period of physical examination with CEA can be elongated for a 6-month 
period for the following 3 years in case of normal results. The CT scan period can be lengthened 
to 1 year for the following 5 years, and the colonoscopic evaluation can be further extended to 
once every 3 years in case of normal previous results.
2.6. Treatment of stage IV CRC
Almost 20–30% of the newly diagnosed CRC patients present with distant metastatic dis-
ease at the time of initial presentation. And, up to 50% of the early-stage CRC patients 
will eventually relapse with metastatic disease. Metastasis can occur in different organs 
and most commonly to the liver (50–60% of the cases). The lungs are less frequent (10–
20%) and are more common in rectal than in colon cancer. Other less often places are the 
peritoneum, ovaries, adrenal glands, bones, and brain. In case of locally recurrent disease 
or with resectable metastases, the standard of care remains curative surgical interven-
tion. Chemoradiotherapy or chemotherapy alone can also be considered an acceptable 
approach in case of rendering a tumor resectable. For non-resectable tumors and/or dis-
seminated metastatic disease, systemic chemotherapy stays the main therapeutic approach. 
Fluoropyrimidines (5-FU and capecitabine) are the mainstay in all protocols used in meta-
static colorectal cancer (mCRC). For nearly 40 years (mid-1950 to 1996), 5-FU was the only 
agent approved for mCRC treatment. Later on, different cytotoxic agents appeared, as the 
topoisomerase I inhibitor (irinotecan) and the third-generation platinum analog (oxalipla-
tin), which both led to considerable advances in mCRC treatment along with fluoropyrimi-
dines. Targeted monoclonal antibodies, such as VEGF inhibitor (bevacizumab) and EGFR 
inhibitor wild-type KRAS (cetuximab and panitumumab), opened a new era in the manage-
ment of mCRC. Many other promising targeted therapies include the anti-VEGF recom-
binant fusion protein (ziv-aflibercept), the dual targeting VEGFR2-TIE2 tyrosine kinase 
inhibitor (regorafenib), the human monoclonal antibody (IgG1) anti-VEGFR2 (ramuci-
rumab), the anti-immune checkpoint programmed cell death protein 1 (PD-1)/programmed 
death-ligand 1 (PD-L1) (nivolumab and pembrolizumab), and the combination of trifluri-
dine, a nucleoside analog, with tipiracil, an inhibitor of the enzyme thymidine phosphory-
lase (trifluridine/tipiracil) which have been approved for combination treatment of mCRC, 
in addition to many other new drugs under investigations.
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2.6.1. Choice of chemotherapy
Various randomized clinical trials have been designed to determine the efficacy of oxaliplatin 
versus irinotecan together with 5-FU/LV or capecitabine. The most well-known trial was the 
GERCOR C97-3 study conducted by Tournigand and coworkers [42] in France which inves-
tigated 5-FU/LV (46-hour infusion) and oxaliplatin (FOLFOX6) compared with 5-FU/LV and 
irinotecan (FOLFIRI) in mCRC. A similar efficacy was observed in both arms with respect to 
overall response rate (ORR, 56% versus 54%, respectively), median time to tumor progression 
(8.5 versus 8.1 months), and median OS (20.6 versus 21.5 months). Similar results were obtained 
by CALGB Cooperative Group (CALGB 80203) and the Hellenic Cooperative Oncology Group 
in Greece. Based on these results, both FOLFOX and FOLFIRI have been approved for first-line 
treatment in mCRC. A meta-analysis of six clinical studies was conducted by Guo et al. [43] to 
investigate the clinical efficacy of the oral capecitabine (Xeloda) plus irinotecan (XELIRI) versus 
FOLFIRI regimen in the first-line treatment of mCRC. The results showed no significant dif-
ferences in terms of ORR, PFS, or OS between the two arms. Another important randomized 
study to compare XELOX non-inferiority with respect to FOLFOX6 in the first-line treatment of 
mCRC was conducted by Ducreux and coworkers [44]. No differences were observed between 
both arms in terms of the clinical efficacy endpoints of ORR (42% versus 46%, respectively), PFS 
(8.8 versus 9.3 months, respectively), and OS (19.9 versus 20.5 months, respectively). Based on 
these and many other studies, it has been established that both protocols FOLFOX and FOLFIRI 
can be safely substituted by oral XELOX and XELIRI in terms of clinical efficacy (PFS and OS).
It is has been proven that doublet chemotherapy has superior clinical efficacy over single-agent 
fluoropyrimidine chemotherapy. However, a new question emerged: is triplet chemotherapy 
with 5-FU, oxaliplatin, and irinotecan can provide improved clinical efficacy over doublet che-
motherapy? To answer this question, the Gruppo Oncologico Nord Ovest (GONO) of Italy 
conducted the first randomized phase III study to compare 5-FU/LV, oxaliplatin, and irinotecan 
(FOLFOXIRI) with FOLFIRI in the front-line setting [45]. After a median follow-up of 5 years, 
the final analysis confirmed the superiority of the FOLFOXIRI regimen over FOLFIRI, in terms 
of improved ORR, PFS, and median OS [46]. However, there was significantly higher grade 2/
grade 3 neurotoxicity (19% versus 0%) and grade 3/grade 4 neutropenia (50% versus 28%) com-
pared with FOLFIRI, the matter that limits the use of this regimen to relatively more fit patient 
population (ECOG performance status 0–1).
2.6.2. Chemotherapy in association with targeted therapy
In order to understand the role of targeted therapy in treating mCRC, we should first perceive 
their mode of action on a molecular level. Bevacizumab (Avastin®) is a recombinant humanized 
monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor 
A (VEGF-A), which stimulates angiogenesis in a variety of diseases, including cancer [47]. In 
2004, bevacizumab has been approved in the United States for use in combination with stan-
dard chemotherapy for metastatic colon cancer. The CALGB/SWOG 80405 phase III randomized 
study compared the potential benefit of cetuximab and bevacizumab added to conventional che-
motherapy (FOLFOX or FOLFIRI) [48]. In contrast to the FIRE study that showed identical ORR 
and PFS, but a 3.7-month improvement in OS toward the cetuximab arm, CALGB/SWOG 80405 
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study showed no significant difference at all either in PFS (10.4 versus 10.8 months) or in OS (29.9 
versus 29.0 months) in patients treated with cetuximab compared with bevacizumab. Recently, 
Venook and coworkers investigated the potential effect of primary tumor location on the clinical 
efficacy of patients treated on CALGB/SWOG 80405 study. It was strange to report that there was 
a significant improvement in OS (p < .0001) for patients with left-sided tumors compared with 
right-sided tumors (33.3 versus 19.4 months). For the bevacizumab arms, the OS was maintained 
high in both groups (left-sided tumors versus right-sided tumors) and significantly higher for 
left-sided primary tumors (31.4 versus 24.2 months). However, in the cetuximab arms, the OS 
in left-sided tumors was 19.3 months (which was 36.0 months) and only 16.7 months for right-
sided tumors. These findings highlighted the importance of sidedness as an important predic-
tive marker and in determining response to anti-EGFR antibody in mCRC [49].
Cetuximab (Erbitux®) and panitumumab (Vectibix®) are both monoclonal antibodies that 
inhibit the epidermal growth factor receptor (EGFR). Both drugs were approved by the FDA 
to treat mCRC that exhibit KRAS wild-type genes in 2009. However, due to high rate of cetux-
imab resistance (45%), further studies identified the role of NRAS and BRAF V600E in treat-
ment response [50]. The KRAS, NRAS, and BRAF are oncogenes that encode proteins involved 
in the mitogen-activated protein kinase (MAPK) signaling pathway, which regulates cell pro-
liferation and survival. Mutations in these genes are found in about 45%, 4%, and 8% of mCRC, 
respectively [51], and this is responsible for activating excess proteins, whose activation does 
not require EGFR upstream signaling, leading to negative feedback loops that limit EGFR acti-
vation, the fact that limits the role of anti-EGFR drugs. Therefore, only the wild type of KRAS 
and NRAS is indicated for the treatment of EGFR inhibitors. Mutation in BRAF V600E was also 
considered as bad indicator in response to EGFR inhibitors and a strong negative prognostic 
marker in mCRC. Data from the randomized phase III Medical Research Council COIN trial 
in mCRC showed an OS of 8.8 versus 14.4 versus 20.1 months, respectively, for patients with 
BRAF-mutant, KRAS exon 2-mutant, and KRAS exon 2 wild type [52]. Moreover, the presence 
of BRAF mutation in mCRC has been associated with big primary tumors (T4), poor histologic 
differentiation, and peritoneal carcinomatosis [53–55].
Due to the poor prognosis factor of the BRAF V600E-mutated gene, many trials tried to estab-
lish a standard treatment for BRAF-mutated mCRC. Vemurafenib is a BRAF enzyme inhibitor, 
which interrupts the B-Raf/MEK step on the B-Raf/MEK/ERK pathway, in case where BRAF 
possesses V600E mutation. In 2017, it has been approved by the FDA for the treatment of 
late-stage melanoma with BRAF V600E-mutated gene. In 2010, a phase I trial for solid tumors 
including colorectal cancer was launched to study the effect of vemurafenib (PLX4032) on 
mCRC patients with mutant BRAF. Unfortunately, the results were not as promising as they 
were in malignant melanoma, with median PFS of 3.7 months [56]. Loupakis and coworkers 
studied in a retrospective exploratory analysis of a phase II trial the effect of FOLFOXIRI regi-
men with bevacizumab on BRAF-mutated mCRC patients. Data found PFS and OS of 11.8 and 
24.1 months, respectively [57]. Two limitations were reported in the study: the first was that 
only patients older than 70 were included, or those who fit (ECOG PS 0) 71–75 old patients, 
and the second was the rarity of BRAF-mutant patients (8% of the population). In TRIBE phase 
III study, FOLFOXIRI regimen was studied either with bevacizumab or alone as first-line 
treatment mCRC, and the median OS was 31 versus 25.8 months in favor of the combination. 
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However, in the mutant BRAF subgroup, the median OS was 13.4 months [58, 59]. According 
to ASCO recommendations in 2017, FOLFOXIRI with or without bevacizumab should be con-
sidered in patients with a BRAF mutation and good performance status.
The programmed death-ligand 1 (PD-L1) with its receptor programmed cell death protein 1 (PD-
1) is T-cell surface checkpoint protein that plays a major role in suppressing the immune system, 
promoting self-tolerance by downregulating T-cell inflammatory activity, and leading to carci-
nogenesis [60]. In the recently updated 2017 NCCN guideline, two novel anti-PD-1 antibodies, 
nivolumab (Opdivo®) and pembrolizumab (Keytruda®), have been indicated as treatment options 
for patients with unresectable MSI-H- or MMR-deficient CRC, although not yet FDA approved 
for mCRC [17]. This was based on the interim results of two ongoing studies: KEYNOTE-016, 
a phase II study of pembrolizumab as monotherapy in MSI-H-/MMR-deficient tumors, and 
CheckMate 142, a study of nivolumab versus nivolumab combination with ipilimumab, another 
monoclonal antibody, in recurrent or mCRC. This decision has been taken into account due to the 
impressive durable response in both studies [61, 62].
Ziv-aflibercept (Zaltrap®), a novel anti-VEGF, is a recombinant fusion protein that consists of 
vascular endothelial growth factor (VEGF)-binding portions from the extracellular domains of 
human VEGF receptors 1 and 2 fused to the Fc portion of the human immunoglobulin (IgG) 1 
[63]. In 2012, it has been approved by the FDA for use in combination with FOLFIRI for the treat-
ment of patients with mCRC that is resistant to or has progressed following an oxaliplatin-con-
taining regimen treatment. A randomized double-blind placebo-controlled global multicenter 
phase III VELOUR trial randomized two groups: one to receive FOLFIRI with ziv-aflibercept 
and the other FOLFIRI with placebo. A statistically significant improvement in OS was observed 
in patients in the FOLFIRI plus ziv-aflibercept group compared with the FOLFIRI plus placebo 
group [HR 0.82 (95% CI, 0.71–0.94), p = 0.0032, stratified log-rank test]. The median OS was 13.5 
versus 12.06 months, and the median PFS was 6.9 versus 4.7 months, respectively, in the ziv-
aflibercept group compared with the placebo group [64].
Regorafenib (Stivarga®), a new oral anti-angiogenic drug, is an oral multi-kinase inhibitor 
which targets angiogenic, stromal, and oncogenic receptor tyrosine kinase (RTK). It inhibits 
many membrane-bound and intracellular kinases that are involved in normal cellular func-
tions and pathologic processes, mainly the VEGFR2-TIE2 tyrosine kinase receptors. In 2012, it 
has been approved by FDA for the treatment of mCRC patients which have been previously 
treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and with 
the anti-VEGF therapy bevacizumab and, if KRAS wild type, with an anti-EGFR therapy. The 
approval was based on the results of an international randomized (2:1), double-blind, pla-
cebo-controlled CORRECT trial. The patients were randomized to get either oral regorafenib 
or placebo. A statistically significant prolongation in overall survival was observed in rego-
rafenib arm [hazard ratio (HR) 0.77 (95% CI 0.64–0.94), p = 0.0102]. The median survival time 
was 6.4 versus 5 months in favor of the regorafenib group (phase III, 2011; FDA, 2012) [65].
Ramucirumab (Cyramza®) is a fully human monoclonal antibody (IgG1), which works by 
blocking the binding of VEGF to its receptor VEGFR2, hence preventing the downstream effect 
of VEGF in angiogenesis. Recently, it has been approved by FDA for use in combination with 
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FOLFIRI for the treatment of patients with mCRC whose disease has progressed on a first-
line regimen containing bevacizumab, oxaliplatin, and fluoropyrimidine [66]. A randomized 
double-blind multinational trial divided patients into FOLFIRI plus ramucirumab-receiving 
group and FOLFIRI plus placebo. A statistically significant improvement in OS was observed 
in patients who received FOLFIRI plus ramucirumab compared with those who received 
FOLFIRI plus placebo [median overall survival 13.3 versus 11.7 months; HR 0.85 (95% CI 0.73–
0.98), p = 0.023, stratified log-rank test]. The DFS was also in favor of ramucirumab arm (5.7 
versus 4.5 months) [67].
Trifluridine/tipiracil (TFD/TPI) (Lonsurf®) is a new combination drug approved in 2015 for the 
treatment of mCRC. It is a combination of two active components: trifluridine, a nucleoside ana-
log, and tipiracil, a thymidine phosphorylase inhibitor, which prevents trifluridine rapid metab-
olism, hence increasing its bioavailability. In 2015, it has been approved by the FDA for use in 
patients with mCRC who have been treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-
based chemotherapy, an anti-vascular endothelial growth factor (VEGF) biological therapy and 
an anti-epidermal growth factor receptor (EGFR) therapy, if RAS wild type [68]. Based on a 
pivotal phase III study (RECOURSE) to assess the efficacy and safety of TFD/TPI compared with 
that of placebo in a large international population, the outcomes were in favor of TFD/TPI arm, 
in terms of median OS (7.1 versus 5.3 months) and median PFS (2.0 versus 1.7 months) [69].
2.6.3. Disease recurrence
In case of recurrence, surgical option for liver or lung metastases should be considered in the 
first place followed by adjuvant chemotherapy, albeit others prefer to administer neoadjuvant 
chemotherapy for 2–3 months before any metastasectomy. In non-resectable tumors and dis-
seminated metastasis, chemotherapy remains the mainstay in treating disease recurrence. It 
should be based on non-previously used protocols, i.e., if FOLFOX was used in previous treat-
ment modalities, FOLFIRI should be the right option, and if both FOLFOX and FOLFIRI have 
been used, the choice shifts toward XELOX or XELIRI. Another alternative is to use infusional 
5-FU or oral capecitabine as monotherapies. Other possibilities are the use of newly approved 
drugs as ziv-aflibercept with FOLOIRI, ramucirumab plus FOLFIRI, oral regorafenib, trifluri-
dine/tipiracil, and nivolumab or pembrolizumab in case of MSI-H or dMMR. According to the 
last NCCN guideline in 2017, adjuvant Stereotactic Body Radiation Therapy (SBRT) should be 
considered in some localized lung or liver lesions. Moreover, the hepatic arterial infusion (HAI) 
pump therapy can be used as a substitute to systemic chemotherapy in unresectable CRC liver 
metastases, where it demonstrated significant tumor response rates [70]. Chemoembolization 
or embolization via radioactive beads is another way to treat liver metastases through the 
hepatic artery in chemorefractory colorectal tumors [71]. In case of peritoneal carcinomato-
sis, a novel strategy has emerged combining cytoreductive peritonectomy with hyperthermic 
intraperitoneal chemoperfusion (HIPEC), with a median survival of 3 years [72]. Many other 
options are being studied to be used as palliative treatment in advanced metastatic disease, 
such as external-beam radiotherapy, photodynamic therapy, cryotherapy, and radiofrequency 
ablation, in addition to oncothermia and many others under trials to palliate and manage the 
disease burden (Table 6).
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2.7. Miscellaneous
2.7.1. Lynch syndrome and familial adenomatous polyposis syndrome
Lynch syndrome, or hereditary nonpolyposis colorectal cancer (HNPCC), is an autosomal dom-
inant disorder that increases the risk of many types of cancer, including endometrial, ovary, 
stomach, small intestine, hepatobiliary tract, upper urinary tract, brain, skin, and particularly 
colon cancer [73]. It is considered the most common hereditary colorectal diseases and accounts 
for 1–3% of all CRC. It is associated with inherited mutation in the mismatch repair (MMR) genes 
MLH1, MSH2, MSH6, and PMS2. This defect in MMR genes leads to tumor DNA microsatellite 
instability (MSI) and promotes carcinogenesis [74]. For this reason MSI profiling with immuno-
histochemistry testing for DNA mismatch repair has been considered essential in diagnosing 
Lynch syndrome (LS). The revised Bethesda guidelines have endorsed the testing for MSI, for 
families at high risk, in any of the following situations in CRC diagnosed in patients <50 years 
of age, the presence of Lynch-associated tumors, and MSI-H identified in patients <60 years old, 
identifying Lynch-related tumors in one or more first-degree relative and in patients <50 years 
of age and identifying Lynch-related tumors in two or more second-degree relatives regardless 
Locally recurrent disease, with 
resectable metastases
Colectomy + metastasectomy
Locally recurrent disease (T4) Chemoradiotherapy or 
chemotherapy alone followed by 
colectomy
Non-resectable tumors and/or 
disseminated metastatic disease
Chemotherapy FOLFOX or FOLFIRI (substitutable by 
XELOX or XELIRI)
FOLFOXIRI (ECOG good performance 
status and BRAF V600E mutation)
Targeted therapy* Bevacizumab (for right-sided tumors)
bevacizumab or cetuximab, or 
panitumumab (for left-sided tumors and 
wild-type KRAS and NRAS genes)
Bevacizumab (for left-sided tumors and 
mutant-type KRAS and NRAS genes)
Disease recurrence Nivolumab or pembrolizumab as 
monotherapy (for MSI-H or dMMR)
FOLFIRI + ziv-aflibercept
FOLFIRI + ramucirumab
Regorafenib as monotherapy
Trifluridine/tipiracil as monotherapy
Clinical trials
*Targeted therapy should be added to chemotherapy, unless otherwise mentioned.
Table 6. Metastatic CRC treatment algorithm.
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of age [75, 76]. The mainstay in the treatment of Lynch syndrome is colectomy. However, due 
to the risk of developing synchronous or metachronous secondary tumors, subtotal colectomy 
with ileorectal anastomosis should be considered in young patients [76]. Recently, three kinds of 
chemotherapy have been investigated for the treatment of LS: 5-FU with leucovorin, oxaliplatin, 
and irinotecan. Most studies showed no benefit of chemotherapy in such patients, just one small 
study on stage IV CRC reported one complete response and three partial responses with MSI-H 
tumors compared to MSI-L/MSS tumors [77]. The use of acetylsalicylic acid (aspirin) as chemo-
prevention by patients with LS is highly supported to reduce the risk of CRC [78]. The Colorectal 
Adenoma/Carcinoma Prevention Programme 2 (CAPP2) trial was conducted to study aspirin 
chemoprevention that has colorectal cancer as the primary endpoint. The initial findings did not 
show any significant difference in colorectal adenoma or cancer formation up to 4 years. In 2010, 
after a longer follow-up (56 months), the results showed a significant decrease in the incidence 
of CRC and LS-related cancers between the aspirin (600 mg) and placebo groups. Prescription of 
aspirin for people at high risk was recommended, but the optimum dose and duration of treat-
ment remain to be established, hopefully in CAPP3 [79]. The colonoscopic surveillance in Lynch 
syndrome is recommended from the age of 20–25 years and repeated at 1–2 years of interval.
Familial adenomatous polyposis (FAP) is an autosomal dominant disorder caused by a germ-
line mutation in the adenomatous polyposis coli (APC) gene, on chromosome 5q21, and char-
acterized by the presence of numerous adenomatous polyps in the colon and rectum. It is 
responsible for about 1% of all CRC cases, and, often, extracolonic manifestations can take 
place as in Gardner syndrome (sebaceous cysts, epidermoid cysts, fibromas, desmoid tumors, 
osteomas, dental anomalies and congenital hypertrophy of the retinal pigment epithelium 
(CHRPE)), Turcot syndrome (brain tumors), gastric and duodenum polyps, soft tissue tumors, 
and thyroid cancers. FAP can be subdivided into classical FAP, attenuated FAP (AFAP), and 
gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) [80]. Clinical diagno-
sis can be based on the number of polyposis, where more than 100 adenomas can be counted 
in case of FAP, from 10 to 99 in case of AFAP, and gastric polyps restricted to the body and fun-
dus of the stomach (gastric fundic gland polyposis) in case of GAPPS [81]. Identification of a 
heterozygous germline pathogenic variant in APC should be confirmed by a molecular genetic 
testing for a definitive diagnosis. Proctocolectomy with ileal pouch-anal anastomosis (IPAA) 
is recommended in case of diffuse spreading out of the polyps with severe familial phenotype 
presence. Total colectomy with ileorectal anastomosis (IRA) is advised in case of scarce adeno-
mas with a mild familial phenotype presence. In AFAP, endoscopic polypectomy can be con-
sidered in case of reduced polyposis number. In GAPPS, gastrectomy is recommended since 
gastric carcinoma is detected in 13% of GAPPS. Regular yearly endoscopic surveillance should 
be taken into account to detect any disease recurrence. In families with classic FAP, endoscopic 
evaluation should begin at age of 12–14 years and be continued lifelong in mutation carriers. 
Regular physical examination and screening via CT scans or MRI for extracolonic manifesta-
tions should also start early in life or as soon as colorectal polyposis is diagnosed [82].
MUTYH-associated polyposis (MAP) is another inheritable form of FAP that is caused by auto-
somal recessive mutations of the MUTYH gene [83]. It accounts for about 10–20% of all polyposis 
patients [2]. Clinically, in MAP patients, between 20 and 99 adenomas should be present upon 
endoscopy [84]; however, a molecular genetic testing is necessary to differentiate between APC 
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and MUTYH mutations [85]. In case of reduce polyposis number, endoscopic polypectomy can 
be sufficient. In case of polyp dissemination all around the colic frame, IPAA is the treatment 
of choice, and if the rectum is intact, IRA can be used to conserve it [85, 86]. Regular annual 
checkup by endoscopy should be maintained in all families presenting MAP disorder [87].
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